Funder
Dr. S. Chandrasekhar, Project Director, NIPER-Hyderabad
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference30 articles.
1. Ambrisentan: a review of its use in pulmonary arterial hypertension;Rivera-Lebron;Ther. Adv. Res. Dis.,2017
2. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension;Kingman;Expert Opin. Pharmacother.,2009
3. Formation of GSH-trapped reactive metabolites in human liver microsomes, S9 fraction HepaRG-cells, and human hepatocytes;Lassila;J. Pharm. Biomed. Anal.,2015
4. Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction;Uetrecht;Drug Metab. Rev.,2006
5. Clinical adverse effects of endothelin receptor antagonists: insights from the meta‐analysis of 4894 patients from 24 randomized double‐blind placebo‐controlled clinical trials;Wei;J. Am. Heart Assoc.,2016
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献